CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0668 (clinicaltrials.gov NCT No: NCT00610493)
Title:A Phase I Trial of Bevacizumab and Temsirolimus in Patients with Advanced Malignancy
Principal Investigator:Sarina Piha-Paul
Treatment Agent:Bevacizumab; CCI-779; Temsirolimus
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of Avastin (bevacizumab) and Torisel (temsirolimus) that can be given, in
combination, to patients with advanced cancer that has spread or is unable to
be surgically removed. The safety of this drug combination will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:Bevacizumab
CCI-779
Temsirolimus
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Not Applicable
Supported By:N/A
Return Visit:Days 1, 8, and 15 every 21 days.
Home Care:The initial doses of Bevacizumab and Temsirolimus will be given in the clinic.
Subsequent doses may be given in the doctor's office in or near their hometown.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sarina Piha-Paul
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults